| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
42,125 |
33,516 |
$2.91M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
29,112 |
23,550 |
$1.36M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
9,469 |
8,086 |
$939K |
| 64483 |
|
6,672 |
4,134 |
$837K |
| 64484 |
|
5,544 |
3,408 |
$535K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
4,105 |
3,301 |
$535K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
2,819 |
2,132 |
$420K |
| 64635 |
|
1,523 |
971 |
$379K |
| 77002 |
|
5,212 |
3,386 |
$296K |
| 64493 |
|
3,449 |
1,484 |
$234K |
| 62321 |
|
2,767 |
2,449 |
$213K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
271 |
207 |
$193K |
| 20610 |
|
4,038 |
2,519 |
$151K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,449 |
3,441 |
$151K |
| 20553 |
|
3,468 |
2,376 |
$127K |
| 64494 |
|
3,332 |
1,450 |
$113K |
| 64636 |
|
1,399 |
917 |
$69K |
| 64633 |
|
246 |
177 |
$68K |
| 27096 |
|
810 |
590 |
$67K |
| 64490 |
|
830 |
361 |
$64K |
| J0735 |
Injection, clonidine hydrochloride, 1 mg |
3,897 |
2,706 |
$57K |
| 80306 |
|
2,535 |
2,041 |
$34K |
| 64634 |
|
239 |
174 |
$31K |
| 64491 |
|
808 |
355 |
$30K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
8,343 |
5,712 |
$24K |
| 64615 |
|
247 |
208 |
$18K |
| J7321 |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
248 |
113 |
$17K |
| 64495 |
|
350 |
145 |
$14K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
10,850 |
7,442 |
$9K |
| 20552 |
|
248 |
190 |
$9K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
506 |
413 |
$7K |
| 64492 |
|
76 |
29 |
$3K |
| 64450 |
|
89 |
68 |
$2K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
90 |
60 |
$623.93 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
516 |
413 |
$607.17 |
| J3490 |
Unclassified drugs |
97 |
67 |
$0.00 |